|Videos|October 14, 2022
Cabozantinib, Nivolumab, and Ipilimumab: Rationale for Use
Author(s)Rana R. McKay, MD
Dr Rana McKay discusses the rationale for using cabozantinib with nivolumab and ipilimumab in the COSMIC 313 trial and reviews the adverse events seen with this combination in the COSMIC 313 trial.
Advertisement
Advertisement
Related to this article
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
Retlirafusp Alfa Improves Overall Survival in Phase 3 Trial of HER2– Gastric Cancer
4
Dr Beck on the Practical Realities of Subcutaneous Oncology Drug Delivery
5